8-K/A: Splash Beverage Group Expands CannEpil License to Veterinary Use

Splash Beverage Group announces an amendment to its exclusive global license for CannEpil, expanding its use to veterinary applications and adjusting royalty rates.

Summary

• Splash Beverage Group, Inc. (SBEV) has amended its exclusive global license agreement with Argent BioPharma Limited for CannEpil.
• The amendment expands the field of use to include veterinary applications, in addition to human applications.
• A new royalty rate structure has been established: 10% of Net Revenue for veterinary applications and 15% for human applications.
• Various deadlines within the original license agreement have been extended.
• Splash intends to pursue U.S. regulatory approval for veterinary use through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways.
• Initial veterinary evaluations will focus on companion-animal oncology and chronic pain management, with a focus on canine indications.
• The company is also finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development due to the strategic expansion into a growing market, but tempered by the acknowledgment of extended deadlines and the inherent risks in pharmaceutical development and regulatory approval.

Positives

• Expansion of the CannEpil platform into the significant and growing veterinary therapeutics market, specifically companion-animal oncology and pain management.
• Establishes a second regulated pharmaceutical development program for Splash, complementing the existing human program.
• The veterinary pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach $3.8 billion by 2030.
• The global veterinary oncology market is estimated between $900 million and $1.7 billion.
• CannEpil is a pharmaceutical-grade cannabinoid formulation manufactured under EU-GMP standards.
• The company is assembling a world-class development platform by partnering with experienced cannabinoid pharmaceutical executives.
• The amendment allows for a lower royalty rate (10%) on net revenues generated from veterinary applications compared to human applications (15%).

Negatives

• The amendment extends various deadlines provided for under the original license agreement, indicating potential delays in development or execution.
• The company is still in the process of finalizing a strategic joint venture for the veterinary development program, with details to be announced in the near future.
• There is no assurance that CannEpil will receive Conditional Approval, full approval, or any other regulatory authorization for veterinary use.
• The company's ability to raise necessary capital for development and commercialization remains a potential challenge.
• The company needs to comply with extensive regulations, including clinical testing, before marketing the product.

Risks

• The possibility that the license and development efforts do not yield anticipated benefits.
• The risk of not being able to obtain, maintain, or protect intellectual property rights for CannEpil.
• Competition from companies marketing similar products.
• Challenges in negotiating and executing a joint venture for the veterinary development program.
• The need to comply with contractual obligations to maintain rights and develop/commercialize the product.
• The ability to raise sufficient capital for development and working capital needs.
• The need to comply with extensive regulations, including clinical testing, before marketing.
• The status of evolving regulatory conditions within the cannabinoid and wellness industries.

Future Outlook

Splash Beverage Group intends to pursue U.S. regulatory approval for CannEpil in veterinary applications through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways. Initial evaluations will focus on companion-animal oncology and chronic pain management, with canine indications as the initial development focus. The company expects to announce additional details regarding a strategic collaboration in the near future. The company's broader strategy includes commercializing existing international pharmaceutical assets, advancing FDA-regulated veterinary and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands.

Management Comments

• "Expanding our exclusive CannEpil license into veterinary medicine materially broadens the value of the platform and provides access to significant companion-animal oncology and pain-management markets," said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group.
• "Cancer and chronic pain affect millions of companion animals, yet treatment options remain limited in many indications. We believe CannEpils pharmaceutical-grade formulation warrants disciplined evaluation through the FDA veterinary process."
• "Our objective extends well beyond expanding the licensed field of use. We are assembling a world-class development platform around CannEpil by partnering with experienced cannabinoid pharmaceutical executives who have successfully navigated complex regulatory pathways and helped bring cannabinoid medicines to market."
• "We believe pairing differentiated intellectual property with proven scientific and regulatory expertise materially enhances our ability to create long-term shareholder value."
• "Splash is executing a disciplined strategy to build a diversified cannabinoid health sciences platform by commercializing existing international pharmaceutical assets, advancing FDA-regulated veterinary and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands for global markets."
• "The expansion of CannEpil into veterinary medicine represents another important milestone in executing that strategy and further positions Splash at the intersection of pharmaceutical innovation and cannabinoid science."

Industry Context

StockSavvy.ai notes that Splash Beverage Group's expansion into veterinary therapeutics with CannEpil aligns with a growing trend in the pharmaceutical industry to leverage existing drug platforms across both human and animal health. The significant market sizes for veterinary oncology and pain management, as highlighted in the filing, present a substantial opportunity. This move also positions Splash to capitalize on the increasing demand for advanced veterinary care and the humanization of pets, where owners are willing to invest in treatments previously only available for humans.

Comparison to Industry Standards

• The filing references the global veterinary pain management market valued at approximately $2.6 billion in 2024, projected to reach $3.8 billion by 2030, indicating a robust growth trajectory comparable to other expanding healthcare sectors.
• The veterinary oncology market, estimated between $900 million and $1.7 billion, shows a significant unmet need, similar to the human oncology market's complexity and demand for novel treatments.
• The pursuit of FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways is a standard regulatory approach for new veterinary drugs in the U.S., mirroring the process for human drug development.
• The use of pharmaceutical-grade cannabinoid formulations (CBD and THC isolates) manufactured under EU-GMP standards is consistent with emerging best practices in the development of cannabinoid-based medicines, aiming for safety and efficacy.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through expansion into new, growing markets and diversification of the company's product pipeline. However, risks associated with development and regulatory approval remain.
• Employees: Potential for growth and new opportunities as the company expands its pharmaceutical development efforts.
• Customers (Veterinary): Potential for new treatment options for companion animals suffering from oncology and chronic pain.
• Suppliers: Potential for increased demand for raw materials and manufacturing services related to CannEpil production for veterinary use.
• Creditors: The company's ability to secure necessary capital for development and commercialization will impact its financial obligations.

Next Steps

• Splash intends to enter into a Development and Collaboration Agreement with Lupvindol UK Limited.
• Splash intends to pursue U.S. regulatory approval for CannEpil for veterinary applications through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways.
• Splash expects to announce additional details regarding the strategic joint venture in the near future.
• The company will continue to execute its diversified cannabinoid health sciences strategy.

Key Dates

Recommendation

The filing indicates a strategic expansion into a promising market with a known product candidate. However, the extended timelines, inherent risks in pharmaceutical development, and the need for further capital and regulatory approvals warrant a cautious 'hold' recommendation. Investors should monitor the progress of the joint venture and regulatory pathways.

Keywords

Cannabinoid Therapeutics, Veterinary Medicine, Pharmaceutical Development, Drug-Resistant Epilepsy, Companion Animal Oncology, Chronic Pain Management, FDA Approval, License Agreement